|1.||Mueller-Ortiz, Stacey L: 3 articles (02/2014 - 01/2004)|
|2.||Wetsel, Rick A: 3 articles (02/2014 - 01/2004)|
|3.||Vaziri, Nosratola D: 2 articles (08/2004 - 06/2002)|
|4.||Hoffmeister, Carin: 1 article (01/2016)|
|5.||Trevisan, Gabriela: 1 article (01/2016)|
|6.||Silva, Cássia R: 1 article (01/2016)|
|7.||Oliveira, Mauro S: 1 article (01/2016)|
|8.||Funck, Vinícius: 1 article (01/2016)|
|9.||Pesquero, João B: 1 article (01/2016)|
|10.||McDougall, Jason J: 1 article (01/2016)|
05/01/1989 - "Complement depletion by prior treatment with cobra venom factor, caused a significant reduction of the thrombocytopenia, whereas DL-2-mercaptomethyl-3-guanidinoethylthiopropanoic acid, an inhibitor of carboxypeptidase N, potentiated the thrombocytopenia elicited by submaximal doses of either IgG aggregates or a homogeneous preparation of rat anaphylatoxin containing C5a. "
02/01/2001 - "In rats, we measured complement activation after hemorrhage and examined the hemodynamic and metabolic effects of complement depletion before injury and worsening of complement activation after hemorrhage and resuscitation [with a carboxypeptidase N inhibitor (CPNI), which blocks the clearance of C5a]. "
09/01/1980 - "The patient with a remarkably low carboxypeptidase N level was a 65-year-old man with an 11-year history of episodic angioedema occurring about 40 times per year. "
09/01/1980 - "Of 172 sera from patients with chronic urticaria or angioedema, one had a remarkably depressed carboxypeptidase N level (21% of normal). "
08/01/1997 - "Given the large overlap in the distributions of carboxypeptidase N and C1 esterase inhibitor levels, prior testing could not be used to evaluate angioedema risk for an individual patient considering angiotensin-converting enzyme inhibitor therapy. "
08/01/1997 - "Small differences in levels of carboxypeptidase N or C1 esterase inhibitor may contribute to an increased risk of angioedema with angiotensin-converting enzyme inhibitor therapy. "
08/01/1997 - "Levels of carboxypeptidase N, total hemolytic complement, C1 esterase inhibitor, and C4, along with questionnaire data, including a history of angioedema-like episodes and family history of angioedema. "
04/01/1997 - "Worthy of note is the finding that in two acute myocardial infarction patients presenting MB2/MB1 ratios lower than the cutoff value (1.5) throughout the period of observation, the baseline values for carboxypeptidase N were higher than in other patients studied. "
04/01/1997 - "In acute myocardial infarction patients carboxypeptidase N showed time-related variations, reaching the highest levels about 48 h after onset of chest pain. "
04/01/1997 - "Furthermore, high baseline levels of carboxypeptidase N will reduce the diagnosis efficiency of creatine kinase-MB isoforms in the diagnosis of acute myocardial infarction."
04/01/1997 - "The results showed a high variability in carboxypeptidase N values among healthy subjects (median = 200 U/l; interquartile range = 190-247 U/l) and in the first available samples from acute myocardial infarction patients (median = 213 U/l; interquartile range = 234 U/l) without significant differences between groups and without a correlation between carboxypeptidase N and creatine activities either in healthy subjects or in acute myocardial infarction patients; in the latter group, however, a significant correlation (p < 0.01) with creatine kinase-MB calculated on all samples, was observed. "
04/01/1997 - "Carboxypeptidase N and creatine kinase-MB isoforms in acute myocardial infarction."
01/01/1984 - "These studies clearly demonstrate that the major regulator system of the complement-derived vasopermeability factors (C3a and C5a) is dramatically depressed during cardiopulmonary bypass and may suggest that the mechanisms of interstitial edema associated with pump lung syndrome may at least, in part, be related to the loss of the serum regulator enzyme carboxypeptidase N, also designated AI."
01/01/1994 - "When a mixture of inhibitors of kininase I (mergepta) and kininase II (captopril) was coinjected with carrageenan, the carrageenan-induced edema was unaffected but the kinin tissue content was significantly enhanced (0.207 +/- 0.003 pmol/g tissue; p < 0.01). "
03/01/1991 - "We also obtained evidence suggesting that, unlike other potentiating peptides, KPP exerts its effect by a mechanism different from the inhibition of kinin metabolism by angiotensin converting enzyme, neutral endopeptidase and kininase I. Here we show the potentiating effect of KPP and of BPP9a, a potentiator derived from snake venom, towards the rat paw edema induced by bradykinin (BK). "
|1.||Complement System Proteins (Complement)
|3.||Immunoglobulin G (IgG)
|4.||cobra venom factor
|6.||Protein Isoforms (Isoforms)
|7.||X-Pro aminopeptidase (aminopeptidase P)
|8.||MB Form Creatine Kinase
|9.||Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)
|10.||Creatine Kinase (Creatine Phosphokinase)
|2.||Cardiopulmonary Bypass (Heart-Lung Bypass)